Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency (Q44173896)

30 November 2017

title

Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency (English)

1 reference

30 November 2017

Ping Chen

1

1 reference

30 November 2017

Edwin J Iwanowicz

2

1 reference

30 November 2017

Derek Norris

3

1 reference

30 November 2017

Henry H Gu

4

1 reference

30 November 2017

James Lin

5

1 reference

30 November 2017

Robert V Moquin

6

1 reference

30 November 2017

Jagabandhu Das

7

1 reference

30 November 2017

John Wityak

8

1 reference

30 November 2017

Steven H Spergel

9

1 reference

30 November 2017

Henry de Fex

10

1 reference

30 November 2017

Suhong Pang

11

1 reference

30 November 2017

Sydney Pitt

12

1 reference

30 November 2017

Ding Ren Shen

13

1 reference

30 November 2017

Gary L Schieven

14

1 reference

30 November 2017

Joel C Barrish

15

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

Bioorganic & Medicinal Chemistry Letters

30 November 2017

published in

1 reference

30 November 2017

volume

12

1 reference

30 November 2017

issue

21

1 reference

30 November 2017

page(s)

3153-3156

1 reference

Profound block in thymocyte development in mice lacking p56lck

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900677-7

7 January 2021

Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900677-7

7 January 2021

The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900677-7

7 January 2021

Signal transduction by lymphocyte antigen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900677-7

7 January 2021

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900677-7

7 January 2021

alpha beta T cell development is abolished in mice lacking both Lck and Fyn protein tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900677-7

7 January 2021

Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900677-7

7 January 2021

Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900677-7

7 January 2021

Tyrosine Kinase Inhibitors. 13. Structure−Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido[4,3-d]pyrimidines Designed as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900677-7

7 January 2021

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900677-7

7 January 2021

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900677-7

7 January 2021

10.1016/S0960-894X(02)00677-7

Identifiers

DOI

1 reference

30 November 2017

1 reference